A phase II study of TALENT (TRIO-USB-12) aimed to evaluate the clinical efficacy and safety of T-DXd monotherapy or T-DXd combined with endocrine therapy in the treatment of early HR positive HER2-low breast cancer patients. The gene discussed is ERBB2; the disease is breast carcinoma.